Cardiovascular disease is the leading cause of death in the world today, and the death rate has remained virtually unchanged in the last 20 years (American Heart Association). This severe life-threatening disease underscores a critical need for developing novel therapeutic strategies to effectively treat this devastating disease. Cell-based therapy represents an extremely promising approach. Generation of induced cardiomyocytes (iCMs) directly from fibroblasts offers an attractive novel strategy for in-situ heart regeneration. Major challenges of iCM reprogramming include the low conversion rate and heterogeneity of the iCMs. This review will summarize the major advancements in improving the iCM reprogramming efficiency and iCM maturation.
INTRODUCTION
Heart disease is the leading cause of death around the world. After heart injury millions of cardiomyocytes are under irreversible necrosis, and infarct area is replaced with fibroblast. Therefore, how to repair injured hearts by regenerative medicine remains as a big challenge. Recently, reprogramming fibroblasts into cardiomyocyte-like cells by introducing three transcription factors (TFs) GATA binding protein 4 (GATA4), myocyte enhancer factor 2C (MEF2C) and T-box 5 (TBX5) (MGT) has shown therapeutic potential. However, major challenges of induced cardiomyocyte (iCM) reprogramming include the low conversion rate and heterogeneity of the iCMs. To address these challenges, multiple strategies have been reported to improve this novel therapeutic approach. In this review, we summarize the major advancements in improving the iCM reprogramming efficiency and iCM maturation. We discuss the inherent relationship between the reprogramming strategies and our understanding of the basic molecular mechanisms of cardiogenesis. We believe creative and combined approaches based on our knowledge of cardiogenesis will continue to contribute heavily in the advancement of iCM reprogramming. We are highly optimistic that iCM reprogramming-based heart therapy may restore the pumping function of damaged patient hearts.
CARDIOGENESIS
Heart is the first organ to develop during embryogenesis. In mammals, the inner cell mass differentiates into ectoderm, mesoderm and endoderm layers after embryo implantation. During gastrulation, the Mesp1 þ cells migrate out from the primitive streak to form lateral plate mesoderm and then cardiac crescent, which is composed of first and second heart fields [1] . During late heart tube and chamber formation, cells from the first heart field mainly contribute to left ventricle and part of atria, and cells from the second heart field contribute to right ventricle, outflow tract and a large percentage of the atria [2] (Fig. 1a ). In addition, cells from proepicardial organ and cardiac neural crest also contribute to the heart formation [3, 4] . Cardiogenesis is a delicate and dynamic process of cell lineage proliferation and differentiation regulated by a unique set of transcriptional and epigenetic networks and signaling pathways ( Fig. 1b ).
Cardiac transcriptional network
Cardiogenesis is regulated by a unique cardiac gene network as extensively studied in mice [5] . During development, several key cardiac specific genes are upregulated at the precise time windows to progressively initiate the cardiogenesis. Shortly after gastrulation, within the Mesp1þ mesoderm cells, the first cardiac-specific TF Nkx2-5 starts to be expressed to initiate cardiogenesis [6] . Following that, GATA4 [7] starts to express at the cardiac crescent and synchronize with Nkx2-5 to further initiate MEF2C [8] expression around E7.5. Around E7.5, other cardiac-specific transcription and epigenetic factors, such as Tbx5 [9] and BAF60c [10] , also start to express. Importantly, these factors work synergistically and often serve as a coactivator to one another to coordinate cardiac gene expression programme. It has been found that Nkx2-5 itself has very limited activating ability, but when cotransfected with GATA4 [7] or Hand2 [11] , a synergized effect in cardiac gene activation is observed. Binding of histone deacetylase and Hopx will change the function of GATA4 from promoting cell proliferation to inducing differentiation [12] . A functional physical interaction between TBX5 and MEF2C is also crucial for early heart development, and these two factors work synergistically to activate the expression of a-cardiac myosin heavy chain (MYH6) [13] . Chromatin remodeling factor BAF60c regulates the interaction of Brg1 with transcription factors such as Tbx5, Nkx2.5 and Gata4 for cardiac gene expression [10] . Those key transcription and epigenetic factors form the core of a precisely regulated cardiac gene network and play an essential role in early heart morphogenesis. Ablation of any of these genes leads to severe heart defects in mice, and mutations in these genes often lead to congenital heart disease [14] .
Cardiogenesis signaling pathways
The development of heart is also tightly regulated by temporal and spatial developmental signals ( Fig. 1b ). Distinct signal pathways regulate different stages of cardiogenesis. For example, Wnt/b-catenin [15] is important for the proliferation of cardiac progenitor cells, whereas fibroblast growth factor (FGF) signal is essential for the proliferation of cardiomyocytes. The knowledge of developmental signals during heart development has greatly benefited the in-vitro differentiation of cardiac cells from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). Specifically, addition of BMP4 and Wnt3a in pluripotent stem cell (PSC) culture, which triggers the gastrulation in vivo, induces PSCs to form mesoderm. Another critical step for in-vitro cardiac differentiation is the cardiac specification of mesoderm cells. Inhibition of Wnt signals by Dickkopfrelated protein 1 or small molecules, which mimics the developmental regulation, greatly increases the differentiation efficiency [16] . Other pathways, such as bone morphogenetic protein, fibroblast growth factor (FGF) and Notch, can also regulate the cardiac differentiation efficiency by time-dependent manner. After cardiomyocyte differentiation, one critical issue is to generate desired subtypes in the adult heart, such as ventricular, atrial and pacemaker cells. Regulating of developmental signals can guide the cardiomyocytes to further differentiated into certain subtypes. For example, it has been shown that inhibition of retinoic acid signal increases the ventricular population, whereas addition of retinoic acid increases the atrial populations [17] . A more detailed study of signaling pathways may help generate various cardiac subtypes via transdifferentiation method.
KEY POINTS
Cardiac reprogramming involves key processes in cardiogenesis as well as removal of fibrotic cell identity.
Highly efficient cardiac reprogramming requires activation of key integrated cardiac transcriptional networks.
Functional cardiac reprogramming also requires the reactivation of core cardiogenesis signaling pathways.
Removal of fibrotic cell identity, a unique epigenetic event in reprogramming, is crucial for cardiac reprogramming.
Changes of epigenetic landscape during cardiogenesis: from mesoderm to cardiomyocytes
In addition to the transcriptional factors and signaling pathways, epigenetic regulation also plays an essential role for the gene regulation during cardiac development. It has been shown that the chromatin structure undergoes progressive changes across genome during differentiation. During cardiac differentiation from ESCs, the pluripotent chromatin landscape is replaced gradually to the cardiomyocyte chromatin landscape (Fig. 1b ). In particular, preactivation of chromatin pattern is observed at the promoters of genes associated with heart development in the early stage of differentiation [5, 18] . For example, the bivalent histone modification is considered as an open chromatin structure for rapid gene activation [19] . During differentiation, the bivalent histone modification on cardiac genes emerges in mesoderm and cardiac progenitor cells, enables rapid activation of cardiac genes in response to development signals. The increase of chromatin accessibilities in the cardiac genes in mesoderm also contributes to the cardiac differentiation [20] . Major epigenetic factors that contribute to these chromatin structural changes are subunit of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex Baf60c, histone methyltransferase Whsc1 and SmyD1, an SET domain-containing protein [16] . 
CARDIAC REPROGRAMMING INVOLVES KEY PROCESSES IN CARDIOGENESIS AS WELL AS REMOVAL OF FIBROTIC CELL IDENTITY

Cardiac transcriptional networks in reprogramming
The initial discoveries in reprogramming to iPSCs, iCMs and other lineage transdifferentiations show that all key factors required are transcription factors. Therefore, numerous efforts to improve iCM efficiency are focused on identifying extra transcription factors. Indeed, it has been shown that adding Hand2 to MGT combination increases reprogramming efficiency both in vitro and in vivo [21] [22] [23] . Other factors, such as Nkx2-5 [24] , Mesp1 [25] and MyoCD [26] , can increase the reprogramming efficiency or improve iCM functions (Fig. 1c) . Although multiple combinations have been applied for reprogramming, MEF2C, GATA4 and TBX5 seem to be irreplaceable. A precise control of gene dosage is required for cardiogenesis and thus, could be required for direct reprogramming, as well. To test the potential effect of gene dosage, one study has taken advantage of the inherent feature of the polycistronic system and generated all possible combinations of G, M, T with identical 2A sequences in a single vector [27 && ]. Their results show that higher protein level of Mef2c combined with lower levels of Gata4 and Tbx5 significantly enhanced reprogramming efficiency compared with separate G, M, T transduction. The optimized gene dosage system also shows 10-fold increase in the number of mature beating iCMs loci. Another interesting observation is that higher protein levels of Gata4 and Tbx5 with a lower level of Mef2c appear to increase the cardiac progenitor cell-related gene expression (NppA and NppB) with no increase in the cardiomyocyte-related genes expression. These data suggest that high Gata4 and Tbx5 with low Mef2c may induce a cardiac progenitor cell (CPC)-like network but not cardiomyocyte network, which is consistent with the observation that GATA4 is more active in CPC stage than in cardiomyocyte stage. The optimized polycistronic vector system was further tested in vivo for iCM reprogramming efficiency after myocardial infarction [28 && ]. As expected, improvement in heart function was observed compared with the traditional separate G, M and T (G/M/T) delivery. All these studies indicate the importance of proper gene dosage in transcriptional gene network for iCM reprogramming.
Cardiac epigenetic factor networks in reprogramming
In addition to transcription factors, various kinds of epigenetic factors are screened and found to enhance reprogramming (Fig. 1c ). Interestingly, it has been discovered that MicroRNAs alone can induce or increase cardiac reprogramming. It has been reported that a combination of cardiac-specific miRNAs (miRNAs 1, 133, 208 and 499; miR combo) is capable of reprogramming fibroblasts to become cardiac myocyte-like cells both in vitro and in vivo [ 
Cardiogenesis signaling pathways in reprogramming
During cardiogenesis, signaling pathways play an important role. The well established cardiomyocytes differentiation protocol from ESCs or iPSCs requires dynamic signaling activation at different stages. For example, FGF2, FGF10 and vascular endothelial growth factor (VEGF) are highly expressed in both developing heart and adult heart and believed to be essential components of the cardiac niches, suggesting that in-vivo cardiac niche could enhance reprogramming efficiency [36] . A number of studies have investigated whether cardiac reprogramming can be guided by signaling pathways (Fig. 1c) . Apart from the early report that VEGF enhances the invivo cardiac cellular reprogramming efficacy [37], one study shows that a combination of FGF2, FGF10 and VEGF (FFV) promotes cardiac reprogramming under defined serum-free conditions (FFV medium) and increases spontaneously beating iCMs by 100-fold [38 && ]. Applying the reprogramming medium at later stage of reprogramming (2 weeks after transduction) appears most efficient.
Moreover, by using FFV medium, functional cardiomyocytes can be induced by only Mef2c and Tbx5 without Gata4. Interestingly, the exactly mediums have been used in the later stage for the differentiation protocol from ESCs or iPSCs to cardiomyocytes [39] . These two processes might share the same mechanism by facilitating further differentiation of either CPCs or immature cardiomyocytes into mature cardiomyocytes.
Recent studies show that certain general expression genes and pathways could also increase the reprogramming efficiency. In one such study, 192 protein kinases are screened and it is observed that constitutively activated Akt/protein kinase B dramatically accelerates and amplifies this process [40 && ]. More importantly, approximately 50% of reprogrammed mouse embryo fibroblasts displayed spontaneous beating after 3-week induction by Akt and GATA4, HAND2, MEF2C and Tbx5 (GHMT). Furthermore, addition of Akt1 to GHMT evokes a more mature cardiac phenotype for iCMs. They further reveal that the enhancing effect of Akt is through activation of mechanistic target of rapamycin and repression of Forkhead box O. Furthermore, insulin-like growth factor 1 can also increase reprogramming efficiency through activating Akt pathway.
Another important difference between developing heart and adult heart is that developing heart is in a hypoxia environment. It has been reported that hypoxic pretreatment of newborn mouse dermal fibroblasts for 6 h can improve the efficiency of iCM reprogramming [41] . Especially, a two-fold increase in cardiac troponin I expression and cardiac Troponin complex been observed. As myocardial infarction-induced heart injury also results in a hypoxic environment in the infarct zone, infarcted heart might facilitate cardiac reprogramming, which is consistent with a better iCM efficiency observed in vivo [21] .
Removal of fibroblast identity and dynamic epigenetic landscape changes during reprogramming
Although cardiac differentiation and cardiac reprogramming may share a similar gene network and regulated by cardiac signaling pathways, these two processes require distinct epigenetic regulation mechanisms (Fig. 1, b and c) . A report studying epigenetic dynamics along the reprogramming process shows that H3K27me3 reduces and H3K4me3 increases at cardiac promoters as early as day 3. In contrast, H3K27me3 at loci encoding fibroblast marker genes does not increase until day 10 and H3K4me3 progressively decreases along the reprogramming process [42 && ]. These results imply that reprogramming efficiency can be improved by two strategies. The first strategy is to rapidly remove repressor signature at cardiac promoters and the second strategy is to remove active signature at the fibro gene promoters (Fig. 1c) .
Removal of the repressor signature at cardiac promoters is exemplified by a Bmi1 knockdown study. By shRNA screen, it has been discovered that shRNA knockdown of Bmi1, a polycomb complex component, significantly enhances induction of beating iCMs from neonatal and adult mouse fibroblasts [34 && ]. Reduced Bmi1 expression corresponds with increased levels of the active histone mark H3K4me3 and reduced levels of repressive H2AK199ub at cardiogenic loci. It appears that shRNA knockdown of Bmi1 also renders GATA4 dispensable. In addition, inhibitors of enhancer of zeste homolog 2 methyltransferase and G9a histone methyltransferase also improve reprogramming efficiency by removing repressor signature at cardiac promoters [43] .
The strategy that removing activate signature at the fibrotic gene promoters to improve iCM efficiency has been supported by a recent study as well [33 && ]. By targeting profibrotic signaling using transforming growth factor-b or Rho-associated kinase pathway inhibitor, the efficiency of converting embryonic fibroblasts into functional cardiomyocyte-like cells increases up to 60% [33 && ]. Spontaneously contracting cardiomyocytes emerge in less than 2 weeks, as opposed to 4 weeks with GHMT alone. Although, change of histone marks in fibrotic gene promoter was not tested directly, the profibrotic signaling network has been attenuated by the inhibitor.
Our laboratory also attempts to identify small molecules that could potentiate the reprogramming ability toward cardiac fate by removing inhibitory roadblocks. We have screened 47 cardiac development-related epigenetic and transcription factors and identified an unexpected role of H3K4 methyltransferase Mll1 in inhibiting iCM reprogramming. We have also applied small molecules to target Mll1 activity and observed an improved efficiency in converting embryonic fibroblasts and cardiac fibroblasts into functional cardiomyocyte-like cells. We further reveal that these inhibitors not only inhibit fibroblast genes, but also directly suppress the expression of Mll1 target genes Ebf1 involved in adipocyte differentiation. Our preliminary results imply that in addition to inhibiting fibroblast gene signature, inhibiting other noncardiac lineage gene signature can also increase the reprogramming efficiency [35 && ].
CHEMICAL INDUCED CARDIOMYOCYTE REPROGRAMMING AND INDUCED CARDIAC PROGENITOR CELL REPROGRAMMING
In addition to the MGT-based cardiac reprogramming discussed above, a number of other strategies of cardiac reprogramming have been reported. Pure chemical-induced reprogramming is an attractive strategy and has been reported in iPSC reprogramming [44] . Using a very similar small molecule combination to iPSC reprogramming [CRFVPTZ (C, CHIR99021; R, RepSox; F, Forskolin; V, valproate; P, Parnate; T, analog of retinoic acid; and Z, DZnep)] with cardiac differentiation medium, beating cardiomyocytes appear to be induced from mouse fibroblasts [45 & ]. Further studies show the chemicalinduced iCMs pass through a cardiac progenitor stage instead of a pluripotent stage. More recently, another group reports the successful reprogramming of human fibroblasts into cardiomyocytes with nine small molecules (CHIR99021, A83-01, BIX01294, AS8351, SC1, Y27632, OAC2, SU16F and JNJ10198409) [46 & ]. Again, the generated iCMs pass through embryonic progenitor cell stage. Interestingly, both combinations contain two common types of inhibitors, GSK3 inhibitor (CHIR99021) and transforming growth factor beta (TGFb) inhibitors (A83-01 and RepSox). TGFb inhibitors are able to increase GHMT-induced cardiac reprogramming [33 && ]. More importantly, CHIR99021 activates wnt3a pathway and promotes cardiac mesoderm lineage commitment during differentiation.
Other cardiac cells have been the targets for reprogramming besides cardiomyocytes. It has been shown that human fibroblast can be reprogrammed into cardiac progenitor cell with Mesp1 and ETS Proto-Oncogene 2 [47] . Recently, a report shows that a combination of cardiac factors (Mesp1, Tbx5, Gata4, Nkx2-5 and Baf60c) and signaling molecules (leukemia inhibitory factor and 6-bromoindirubin-3'-oxime) can reprogram adult mouse fibroblasts into expandable induced cardiac progenitor cells [48 && ]. Interestingly, the combination is very similar to cardiomyocyte reprogramming combination except without Mef2C. Using iPSC reprogramming factors to convert fibroblasts into CPCs has been reported as well [49] .
CONCLUSION
In summary, cardiac reprogramming is a promising strategy for heart therapy and significant progress has been made in the past 2 years to increase the efficiency and function of iCMs. In the near future, we anticipate continued progress in basic mechanistic studies to provide new directions for reprogramming. Applying cutting-edge technologies, such as single-cell based genome-wide gene expression and chromatin assays and Cas9-based genome editing technology, will push the field forward. We are particularly intrigued by the discoveries in epigenetic field that removing epigenetic barriers can greatly increase the reprogramming efficiency and iCM maturation. More potent reprogramming factors, including TFs, epigenetic factors and lncRNAs, will be identified and an optimized combination will produce mature and functional iCMs with high efficiency. We also expect that with the identification of signaling and small molecules in promoting iCM reprogramming, a much efficient reprogramming culture medium can be developed. It will precisely control cardiac reprogramming at different stages with different conditions. To translate the iCM strategy into clinical studies, a shifted focus on human cell reprogramming and novel approaches for in-vivo studies should be considered. Although the virus-based gene introduction strategy has some advantages for long-term stable gene expression, the disadvantage of virus integration is a big concern for potential tumorigenesis. Alternative nonintegrated strategies, such as mRNA or protein-mediated reprogramming, should be thoroughly investigated.
